MartinTallmanMD

PubMed

• Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes.
  B Bishal Paudel, Su-Fern Tan, Todd E Fox, Johnson Ung, Upendarrao Golla, Jeremy J P Shaw, Wendy Dunton, Irene Lee, Wisam A Fares, Satyam Patel, Arati Sharma, Aaron D V...> ;Blood Advances. 2024 Mar 12
• Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.
  Vigil, C., Collins, R., Jain, V., Wang, E., Goldberg, A., Tallman, M., Walter, R., Karanes, C., Sandhu, K., Stone, R.> ;Journal of Clinical Oncology. 2024 Feb 7
• How to avoid early mortality in acute promyelocytic leukemia.
  Odetola, O., Tallman, M.> ;Hematology. American Society of Hematology. Education Program. 2023 Dec 8
• Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.
  Ryan N Ptashkin, Mark D Ewalt, Gowtham Jayakumaran, Iwona Kiecka, Anita S Bowman, JinJuan Yao, Jacklyn Casanova, Yun-Te David Lin, Kseniya Petrova-Drus, Abhinita S Moh...> ;Nature Communications. 2023 Oct 28
• 3 citations
  Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial.
  Despoina Papazoglou, Tait D Shanafelt, Nikolaos Ioannou, Giulia De Rossi, Sylvia Herter, Marina Bacac, Christian Klein, Martin S Tallman, Neil E Kay, Alan G Ramsay, Xi...> ;Blood. 2024 Jan 4
• 1 citations
  Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia.
  Devlin, S., von Keudell, G., Vemuri, S., Shukla, M., Falco, V., Cuello, B., Park, J., Durham, B., Winer, E., Huntington, S., Gore, S., Stone, R., Abdel-Wahab, O., Tall...> ;NEJM Evidence. 2023 Oct 1
• 1 citations
  What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?
  Susan DeWolf, Martin S Tallman, Jacob M Rowe, Meira Yisraeli Salman> ;Journal of Clinical Oncology. 2023 Oct 10
• Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999.
  Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, Duane Hassane, Timour Baslan, Daniel T Gildea, Samuel Haddox, Tak Lee, H Moses Murdock, Caroline Sheridan, Alexis...> ;Blood Cancer Journal. 2023 Jul 6
• 3 citations
  Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.
  Sara Zarnegar-Lumley, Todd A Alonzo, Robert B Gerbing, Megan Othus, Zhuoxin Sun, Rhonda E Ries, Jim Wang, Amanda Leonti, Matthew A Kutny, Fabiana Ostronoff, Jerald P R...> ;Blood Advances. 2023 Oct 10
• 5 citations
  Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.
  Joseph G W McCarter, David Nemirovsky, Christopher A Famulare, Noushin Farnoud, Abhinita S Mohanty, Zoe S Stone-Molloy, Jordan Chervin, Brian J Ball, Zachary D Epstein...> ;Blood Advances. 2023 Sep 12
• 1 citations
  Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis.
  James M Foran, Zhuoxin Sun, Catherine Lai, Hugo F Fernandez, Larry D Cripe, Rhett P Ketterling, Janis Racevskis, Selina M Luger, Elisabeth Paietta, Hillard M Lazarus, ...> ;Cancer. 2023 Aug 15
• 11 citations
  North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
  Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R Wilson, Marina Konopleva, Arthur E Frankel, Vikas Gupta, Ruben Mesa, Matth...> ;Blood. 2023 Feb 9
• 3 citations
  The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study.
  Ibrahim Aldoss, Jun Yin, Anna Wall, Krzysztof Mrózek, Michaela Liedtke, David F Claxton, Matthew C Foster, Frederick R Appelbaum, Harry P Erba, Mark R Litzow, Martin S...> ;Blood Advances. 2023 Jan 24
• 1 citations
  DNA polymerase θ protects leukemia cells from metabolically induced DNA damage.
  Umeshkumar Vekariya, Monika Toma, Margaret Nieborowska-Skorska, Bac Viet Le, Marie-Christine Caron, Anna-Mariya Kukuyan, Katherine Sullivan-Reed, Paulina Podszywalow-B...> ;Blood. 2023 May 11
• 3 citations
  Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.
  Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timoth...> ;Blood Cancer Journal. 2022 Dec 13
• 1 citations
  Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.
  Chezi Ganzel, Zhuoxin Sun, Timour Baslan, Yanming Zhang, Mithat Gönen, Omar I Abdel-Wahab, Janis Racevskis, Francine Garrett-Bakelman, Scott W Lowe, Hugo F Fernandez, ...> ;Leukemia Research. 2022 Dec 1
• 2 citations
  Development of a distributed international patient data registry for hairy cell leukemia.
  Leslie A Andritsos, Mirela Anghelina, Jasmine Neal, James S Blachly, Puneet Mathur, Omkar Lele, Claire Dearden, Sunil Iyengar, Matthew Cross, Clive S Zent, Kerry A Rog...> ;Leukemia & Lymphoma. 2022 Dec 1
• 2 citations
  Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia.
  Diego A Pereira-Martins, Juan L Coelho-Silva, Isabel Weinhäuser, Pedro L Franca-Neto, Douglas R Silveira, César Ortiz, Amanda Moreira-Aguiar, Marinus M Lima, Luisa C K...> ;British Journal of Haematology. 2023 Jan 1
• 2 citations
  Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
  Maximilian Stahl, Andriy Derkach, Noushin Farnoud, Jan Philipp Bewersdorf, Troy Robinson, Christopher Famulare, Christina Cho, Sean Devlin, Kamal Menghrajani, Minal A ...> ;American Journal of Hematology. 2023 Jan 1
• 1 citations
  Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999.
  Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, Duane Hassane, Timour Baslan, Daniel T Gildea, Samuel Haddox, Tak Lee, H Moses Murdock, Caroline Sheridan, Alexis...> ;Blood Cancer Journal. 2022 Sep 23
• 592 citations
  Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
  Hartmut Döhner, Andrew H Wei, Frederick R Appelbaum, Charles Craddock, Courtney D DiNardo, Hervé Dombret, Benjamin L Ebert, Pierre Fenaux, Lucy A Godley, Robert P Hass...> ;Blood. 2022 Sep 22
• 7 citations
  Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.
  Johnson Ung, Su-Fern Tan, Todd E Fox, Jeremy J P Shaw, Luke R Vass, Pedro Costa-Pinheiro, Francine E Garrett-Bakelman, Michael K Keng, Arati Sharma, David F Claxton, R...> ;Blood Reviews. 2022 Sep 1
• 11 citations
  Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
  Nikolaus Jahn, Ekaterina Jahn, Maral Saadati, Lars Bullinger, Richard A Larson, Tiziana Ottone, Sergio Amadori, Thomas W Prior, Joseph M Brandwein, Frederick R Appelba...> ;Leukemia. 2022 Sep 1
• 6 citations
  Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia.
  Lori Muffly, Jun Yin, Sawyer Jacobson, Anna Wall, Elisa Quiroz, Anjali S Advani, Selina M Luger, Martin S Tallman, Mark R Litzow, Matthew C Foster, Harry P Erba, Frede...> ;Blood Advances. 2022 Jul 26
• 82 citations
  Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
  Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, Elisabeth M Paietta, Susan O'Brien, Jacqueline Barrientos, Diane F Jelinek, Esteban Braggio, Jose F Leis, Cong Ch...> ;Blood. 2022 Jul 14
• Join now to see all

Journal Articles

• Extramedullary Acute Myeloid Leukemia Presenting in Young Adults Demonstrates Sensitivity to High Dose Anthracycline: Subset Analysis from ECOG-ACRIN 1900  
  Selina M Luger, Ross L Levine, Martin S Tallman, Haematologica
• Acquired Resistance to IDH Inhibition Through Trans or Cis Dimer-Interface Mutations  
  Martin S Tallman, Eytan M Stein, Alan H Shih, Maria E Arcila, Andrew M Intlekofer, Craig B Thompson, Mikhail Roshal, Nature
• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
• Phase 2b Study of Two Dosing Regimens of Quizartinib Monotherapy in FLT3-ITD Mutated, Relapsed or Refractory AML  
  Alexander E Perl, Mark J Levis, Stuart L Goldberg, Martin S Tallman, Hagop M Kantarjian, Gary J Schiller, Blood
• Join now to see all

Abstracts/Posters

• Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Anal...
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leu...
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Resul...
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelody...
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Acute Leukemia with Lineage Infidelity: Mixed Phenotype AML Exhibits a Distinct Immunophenotype with Clinical Features Overlapping Mixed Phenotype Acute Leukemia
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young ...
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Pegaspargase Can Safely be Administered in Adults Age 40 and Older with Acute Lymphoblastic Leukemia
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• AML with Mutations in IDH1 and DNMT3A Exhibits a Distinct Epigenetic Signature with Poorer Overall Survival 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Hematologic Malignancies Arising in Patients with Germ Cell Tumors: Secondary Somatic Differentiation of Hematopoietic Malignancies from Germ Cell Precursors 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Hypofibrinogenemia and Disseminated Intravascular Coagulation Rarely Complicate Treatment-Naive Acute Lymphoblastic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Changing Game Plan for Acute Lymphocytic Leukemia: Emerging Treatment Options and Progressive Approaches to Patient Care 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Join now to see all

Other

• Clinical features and diagnosis of hairy cell leukemia 
  Tallman MS, Aster JC
  http://www.uptodate.com/contents/clinical-features-and-diagnosis-of-hairy-cell-leukemia
  UpToDate, Wolters Kluwer Health - 2013-04-02
• Treatment of hairy cell leukemia 
  Tallman MS
  http://www.uptodate.com/contents/treatment-of-hairy-cell-leukemia
  UpToDate, Wolters Kluwer Health - 2012-12-12